Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07082179 | A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer | recruiting | Phase 2 | 33 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04930432 | Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors | recruiting | Phase 1 / Phase 2 | 400 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Feb 10, 2026 |
| clinicaltrials |
| NCT05167487 | Pathological Response After Neoadjuvant Treatment on NSCLC(PLANET) | recruiting | — | 150 | Fundación GECPOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05234307 | PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | recruiting | Phase 1 | 30 | Dwight OwenOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07392658 | Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.(AMICUTE) | recruiting | Phase 2 | 33 | Fondazione Ricerca TraslazionaleOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05236114 | GEMINI-NSCLC: NSCLC Biomarker Study | recruiting | — | 1,200 | Tempus AIINDUSTRY | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05620342 | Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer | recruiting | Early Phase 1 | 24 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06221800 | Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects | recruiting | — | 82 | University of California, IrvineOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06472804 | Insomnia in Patients With Metastatic Lung Cancer | recruiting | — | 60 | Mayo ClinicOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06945484 | PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study(PILOT PERCC) | recruiting | N/A | 20 | University of UtahOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT02570815 | Near-Infrared Fluorescence Guided Robotic Pulmonary Segmentectomy for Early Stage Lung Cancer | recruiting | Phase 1 | 250 | St. Joseph's Healthcare HamiltonOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT03953144 | Synapse 3D With Intravascular Indocyanine Green | recruiting | Phase 1 / Phase 2 | 32 | St. Joseph's Healthcare HamiltonOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04339218 | Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma(CRYOMUNE) | recruiting | Phase 3 | 214 | Institut BergoniéOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06484491 | IMPT Dose Escalation for NSCLC (HyDose)(HyDose) | recruiting | N/A | 87 | University Medical Center GroningenOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06639191 | [177Lu]Lu-AKIR001 First-in-human Study(AKIR001) | recruiting | Early Phase 1 | 15 | Karolinska University HospitalOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07374614 | Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib(SAILOR) | recruiting | — | 20 | Peking University Shenzhen HospitalOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07376707 | A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors(TGI5) | recruiting | Phase 1 | 194 | Hefei TG ImmunoPharma Co., Ltd.OTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04467723 | Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC | recruiting | Phase 1 / Phase 2 | 25 | University of Kansas Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06634199 | Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients(SIENNA) | recruiting | — | 50 | Fundación GECPOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07151040 | Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors(ODIN) | recruiting | Phase 1 / Phase 2 | 43 | One-carbon Therapeutics ABINDUSTRY | 3 | Jan 28, 2026 | clinicaltrials |
| NCT07371663 | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 266 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05467748 | EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 66 | VA Office of Research and DevelopmentFED | 1 | Jan 27, 2026 | clinicaltrials |
| NCT06810609 | Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC(InDuRanS) | recruiting | Phase 2 | 176 | University Hospital, BonnOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07363811 | Large Granular Lymphocytes in mNSCLC Treated With Nivolumab | recruiting | — | 50 | Necmettin Erbakan UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT05502523 | The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer | recruiting | N/A | 100 | Thomas Jefferson UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07348211 | First in Human Study of SIM0610 in Solid Tumors(SIM0610-101) | recruiting | Phase 1 | 260 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07362459 | A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer. | recruiting | Phase 3 | 246 | Sinocelltech Ltd.INDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07362940 | A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib | recruiting | Phase 1 / Phase 2 | 110 | Henan Genuine Biotech Co., Ltd.INDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07358806 | Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 51 | Oscotec Inc.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06481813 | Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients(BREATHE) | recruiting | N/A | 730 | Nantes University HospitalOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06612840 | A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors | recruiting | Phase 1 | 20 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06576635 | LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients(LUNG-05) | recruiting | N/A | 29 | University of Illinois at ChicagoOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06227728 | Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.(PTC-IMPACT) | recruiting | — | 50 | Gene SolutionsINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07219576 | Retifanlimab and Ruxolitinib In Solid Malignancies(PRISM) | recruiting | Phase 1 / Phase 2 | 40 | University of California, San DiegoOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT06908304 | A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC | recruiting | Phase 3 | 300 | Maia BiotechnologyINDUSTRY | 4 | Jan 12, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06073431 | LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia(LOTUS) | recruiting | — | 800 | University of RochesterOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07328945 | Patient-derived Tumor-like Cell Cluster Model-based Precision Treatment Strategy on Non-small Cell Lung Cancer | recruiting | — | 250 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07330037 | TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy | recruiting | Phase 2 | 41 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07330050 | WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC | recruiting | Phase 2 | 31 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07330596 | QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC | recruiting | Phase 2 | 96 | Anhui Provincial Cancer HospitalOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05613413 | A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)(LUNG-IST-127) | recruiting | Phase 2 | 36 | University of Illinois at ChicagoOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07161310 | Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors(MitoCancer) | recruiting | N/A | 45 | Goethe UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07325864 | Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site | recruiting | — | 25 | European Institute of OncologyOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06999187 | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | recruiting | Phase 1 | 96 | Dren BioINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07323056 | Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer | recruiting | Phase 2 | 36 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07320105 | Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II) | recruiting | Phase 4 | 60 | Fujian Cancer HospitalOTHER_GOV | 1 | Jan 6, 2026 | clinicaltrials |
| NCT06627738 | Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost(Cybertaxcis II) | recruiting | Phase 2 | 42 | Centre Antoine LacassagneOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06903377 | Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 50 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Feb 11, 2026source: clinicaltrials